Shopping Cart

Remove All

Your shopping cart is currently empty

Proceed to checkout Continue shopping

XL041

Name: XL041
Brand: TargetMol
SKU: T14679
Rating: 4.5 (1 reviews)

😃Good

Catalog No. T14679Cas No. 1256918-39-4

Alias BMS-852927

XL041 (BMS-852927) is an agonist selective for LXRβ.

XL041

😃Good

Catalog No. T14679Alias BMS-852927Cas No. 1256918-39-4

XL041 (BMS-852927) is an agonist selective for LXRβ.

Pack Size	Price	USA Warehouse	Global Warehouse
5 mg	Inquiry	8-10 weeks	8-10 weeks
25 mg	Inquiry	8-10 weeks	8-10 weeks
50 mg	Inquiry	8-10 weeks	8-10 weeks
100 mg	Inquiry	8-10 weeks	8-10 weeks
1 mL x 10 mM (in DMSO)	Inquiry	8-10 weeks	8-10 weeks

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products. However, due to objective factors, there is a small probability that the synthesis may not be successful during the R&D process. We appreciate your understanding. If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.

Questions

Resource Download

Product Introduction

Bioactivity

Description	XL041 (BMS-852927) is an agonist selective for LXRβ.
In vitro	XL041 (BMS-852927) functions as an LXRβ-selective agonist, exhibiting 20% activity towards LXRα and 88% towards LXRβ relative to a comprehensive pan agonist in transactivation assays. Despite similar binding affinities to LXRα and LXRβ (19 and 12 nM, respectively)[1], XL041 proves to be potent, with an EC50 of 9 nM and achieves 26% activity in an in vitro human whole-blood endogenous target gene activation assay (WBA).
In vivo	XL041 (BMS-852927) exhibits a highly favorable efficacy profile at therapeutic doses in both cynomolgus monkeys and mice. In a distinct study, the compound effectively inhibited the progression of atherosclerosis over a 12-week period in LDLR knockout (KO) mice. Additionally, pre-treating C57BL/6J mice with XL041 for seven days induced a potent and dose-dependent increase in cholesterol efflux, peaking at a 70% enhancement over the control with a dose of 3 mg/kg/day. This effect was also observed in LDLR KO mice. Notably, the dosage range that inhibits atherosclerosis (0.1-3 mg/kg/day) aligns closely with the dosage range that stimulates macrophage reverse cholesterol transport (RCT) (0.03-3 mg/kg/day), indicating a conserved mechanism of action for LXR agonists in mitigating the disease.
Synonyms	BMS-852927

Chemical Properties

Molecular Weight	609.51
Formula	C₂₉H₂₈Cl₂F₂N₂O₄S
Cas No.	1256918-39-4
Smiles	CC(C)(O)c1cn(c(n1)C(C)(C)c1c(Cl)cccc1Cl)-c1ccc(cc1F)-c1cc(F)c(CO)c(c1)S(C)(=O)=O
Relative Density.	1.36 g/cm3 (Predicted)

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 100 mg/mL (164.07 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (5.41 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	1.6407 mL	8.2033 mL	16.4066 mL	82.0331 mL
5 mM	0.3281 mL	1.6407 mL	3.2813 mL	16.4066 mL
10 mM	0.1641 mL	0.8203 mL	1.6407 mL	8.2033 mL
20 mM	0.0820 mL	0.4102 mL	0.8203 mL	4.1017 mL
50 mM	0.0328 mL	0.1641 mL	0.3281 mL	1.6407 mL
100 mM	0.0164 mL	0.0820 mL	0.1641 mL	0.8203 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc